APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiplex Immunofluorescence (mIF) Technology

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Multiplex Immunofluorescence (mIF) Technology Market Analysis and Forecast 2026-2032

6 March 2026193 pages

Choose your research edition.

Industry ResearchMultiplex Immunofluorescence (mIF) Technology Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiplex Immunofluorescence (mIF) Technology Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Multiplex Immunofluorescence (mIF) Technology Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiplex Immunofluorescence (mIF) Technology Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiplex Immunofluorescence (mIF) Technology Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Multiplex Immunofluorescence (mIF) Technology market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Multiplex Immunofluorescence (mIF) Technology is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Multiplex Immunofluorescence (mIF) Technology is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Multiplex Immunofluorescence (mIF) Technology is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Multiplex Immunofluorescence (mIF) Technology is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Multiplex Immunofluorescence (mIF) Technology include Eureka Biotech, ICON plc, Discovery Life Sciences, Precision Medicine Group, Terry Technologies, MGI Tech, panovue, Biospective and iCuraDx, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Multiplex Immunofluorescence (mIF) Technology, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Multiplex Immunofluorescence (mIF) Technology, also provides the revenue of main regions and countries. Of the upcoming market potential for Multiplex Immunofluorescence (mIF) Technology, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Multiplex Immunofluorescence (mIF) Technology revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Multiplex Immunofluorescence (mIF) Technology market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Multiplex Immunofluorescence (mIF) Technology revenue, projected growth trends, production technology, application and end-user industry.

Multiplex Immunofluorescence (mIF) Technology Segment by Company

Eureka Biotech

ICON plc

Discovery Life Sciences

Precision Medicine Group

Terry Technologies

MGI Tech

panovue

Biospective

iCuraDx

Yucebio

Flagship Biosciences

Lanterne Dx (LDX)

Crown Bioscience

Multiplex Immunofluorescence (mIF) Technology Segment by Type

Direct Labeling mIF Technology

TSA-based Amplification mIF Technology

Dual-amplification mIF Technology

Multiplex Immunofluorescence (mIF) Technology Segment by Application

Tumor Immunology Research

Clinical Pathological Diagnosis

Immune Microenvironment Profiling

Other

Multiplex Immunofluorescence (mIF) Technology Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiplex Immunofluorescence (mIF) Technology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiplex Immunofluorescence (mIF) Technology and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiplex Immunofluorescence (mIF) Technology.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Multiplex Immunofluorescence (mIF) Technology in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Multiplex Immunofluorescence (mIF) Technology company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multiplex Immunofluorescence (mIF) Technology revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Multiplex Immunofluorescence (mIF) Technology Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Direct Labeling mIF Technology Major Player Table 3. TSA-based Amplification mIF Technology Major Player Table 4. Dual-amplification mIF Technology Major Player Table 5. Global Multiplex Immunofluorescence (mIF) Technology Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Tumor Immunology Research Major Player Table 7. Clinical Pathological Diagnosis Major Player Table 8. Immune Microenvironment Profiling Major Player Table 9. Other Major Player Table 10. Multiplex Immunofluorescence (mIF) Technology Industry Trends Table 11. Multiplex Immunofluorescence (mIF) Technology Industry Drivers Table 12. Multiplex Immunofluorescence (mIF) Technology Industry Opportunities and Challenges Table 13. Multiplex Immunofluorescence (mIF) Technology Industry Restraints Table 14. Global Multiplex Immunofluorescence (mIF) Technology Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Multiplex Immunofluorescence (mIF) Technology Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Multiplex Immunofluorescence (mIF) Technology Market Share by Region (2021-2026) Table 17. Global Multiplex Immunofluorescence (mIF) Technology Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Multiplex Immunofluorescence (mIF) Technology Market Share by Region (2027-2032) Table 19. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Players (2021-2026) Table 21. Global Multiplex Immunofluorescence (mIF) Technology Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Multiplex Immunofluorescence (mIF) Technology Key Players Headquarters & Area Served Table 23. Global Multiplex Immunofluorescence (mIF) Technology Players, Product Type & Application Table 24. Global Multiplex Immunofluorescence (mIF) Technology Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Multiplex Immunofluorescence (mIF) Technology by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Type (2021-2026) Table 31. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Type (2027-2032) Table 32. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Application (2021-2026) Table 36. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Application (2027-2032) Table 37. Eureka Biotech Company Information Table 38. Eureka Biotech Business Overview Table 39. Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 41. Eureka Biotech Recent Development Table 42. ICON plc Company Information Table 43. ICON plc Business Overview Table 44. ICON plc Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. ICON plc Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 46. ICON plc Recent Development Table 47. Discovery Life Sciences Company Information Table 48. Discovery Life Sciences Business Overview Table 49. Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 51. Discovery Life Sciences Recent Development Table 52. Precision Medicine Group Company Information Table 53. Precision Medicine Group Business Overview Table 54. Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 56. Precision Medicine Group Recent Development Table 57. Terry Technologies Company Information Table 58. Terry Technologies Business Overview Table 59. Terry Technologies Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Terry Technologies Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 61. Terry Technologies Recent Development Table 62. MGI Tech Company Information Table 63. MGI Tech Business Overview Table 64. MGI Tech Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. MGI Tech Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 66. MGI Tech Recent Development Table 67. panovue Company Information Table 68. panovue Business Overview Table 69. panovue Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. panovue Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 71. panovue Recent Development Table 72. Biospective Company Information Table 73. Biospective Business Overview Table 74. Biospective Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Biospective Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 76. Biospective Recent Development Table 77. iCuraDx Company Information Table 78. iCuraDx Business Overview Table 79. iCuraDx Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. iCuraDx Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 81. iCuraDx Recent Development Table 82. Yucebio Company Information Table 83. Yucebio Business Overview Table 84. Yucebio Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Yucebio Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 86. Yucebio Recent Development Table 87. Flagship Biosciences Company Information Table 88. Flagship Biosciences Business Overview Table 89. Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 91. Flagship Biosciences Recent Development Table 92. Lanterne Dx (LDX) Company Information Table 93. Lanterne Dx (LDX) Business Overview Table 94. Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 96. Lanterne Dx (LDX) Recent Development Table 97. Crown Bioscience Company Information Table 98. Crown Bioscience Business Overview Table 99. Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 101. Crown Bioscience Recent Development Table 102. North America Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. North America Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021-2026) & (US$ Million) Table 108. North America Multiplex Immunofluorescence (mIF) Technology Revenue by Country (US$ Million) & (2027-2032) Table 109. Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021-2026) & (US$ Million) Table 115. Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Country (US$ Million) & (2027-2032) Table 116. China Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026) & (US$ Million) Table 117. China Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032) & (US$ Million) Table 118. China Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026) & (US$ Million) Table 119. China Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026) & (US$ Million) Table 123. Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Region (US$ Million) & (2021-2026) Table 126. Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Region (US$ Million) & (2027-2032) Table 127. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026) & (US$ Million) Table 128. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032) & (US$ Million) Table 129. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026) & (US$ Million) Table 130. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032) & (US$ Million) Table 131. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021-2026) & (US$ Million) Table 133. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Country (US$ Million) & (2027-2032) Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Multiplex Immunofluorescence (mIF) Technology Image Figure 2. Global Multiplex Immunofluorescence (mIF) Technology Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiplex Immunofluorescence (mIF) Technology Market Size Share 2021 VS 2025 VS 2032 Figure 4. Direct Labeling mIF Technology Image Figure 5. TSA-based Amplification mIF Technology Image Figure 6. Dual-amplification mIF Technology Image Figure 7. Global Multiplex Immunofluorescence (mIF) Technology Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Multiplex Immunofluorescence (mIF) Technology Market Size Share 2021 VS 2025 VS 2032 Figure 9. Tumor Immunology Research Image Figure 10. Clinical Pathological Diagnosis Image Figure 11. Immune Microenvironment Profiling Image Figure 12. Other Image Figure 13. Global Multiplex Immunofluorescence (mIF) Technology Market Size (US$ Million) & (2021-2032) Figure 14. Global Multiplex Immunofluorescence (mIF) Technology Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Multiplex Immunofluorescence (mIF) Technology Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Multiplex Immunofluorescence (mIF) Technology Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Type (2021-2032) Figure 21. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Application (2021-2032) Figure 24. North America Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032) Figure 26. North America Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032) Figure 27. North America Multiplex Immunofluorescence (mIF) Technology Revenue Share by Country (2021-2032) Figure 28. United States Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032) Figure 33. Europe Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032) Figure 34. Europe Multiplex Immunofluorescence (mIF) Technology Revenue Share by Country (2021-2032) Figure 35. Germany Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032) Figure 45. China Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032) Figure 46. Asia Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032) Figure 48. Asia Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032) Figure 49. Asia Multiplex Immunofluorescence (mIF) Technology Revenue Share by Region (2021-2032) Figure 50. Japan Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032) Figure 58. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032) Figure 59. SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue Share by Country (2021-2032) Figure 60. Brazil Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Multiplex Immunofluorescence (mIF) Technology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Direct Labeling mIF Technology
  • TSA-based Amplification mIF Technology
  • Dual-amplification mIF Technology
Applications
  • Tumor Immunology Research
  • Clinical Pathological Diagnosis
  • Immune Microenvironment Profiling
  • Other
Companies covered
  • Eureka Biotech
  • ICON plc
  • Discovery Life Sciences
  • Precision Medicine Group
  • Terry Technologies
  • MGI Tech
  • panovue
  • Biospective
  • iCuraDx
  • Yucebio
  • Flagship Biosciences
  • Lanterne Dx (LDX)
  • Crown Bioscience

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Multiplex Immunofluorescence (mIF) Technology Market by Type
  3. 1.2.1 Global Multiplex Immunofluorescence (mIF) Technology Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Direct Labeling mIF Technology
  5. 1.2.3 TSA-based Amplification mIF Technology
  6. 1.2.4 Dual-amplification mIF Technology
  7. 1.3 Multiplex Immunofluorescence (mIF) Technology Market by Application
  8. 1.3.1 Global Multiplex Immunofluorescence (mIF) Technology Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Tumor Immunology Research
  10. 1.3.3 Clinical Pathological Diagnosis
  11. 1.3.4 Immune Microenvironment Profiling
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Multiplex Immunofluorescence (mIF) Technology Market Dynamics
  1. 2.1 Multiplex Immunofluorescence (mIF) Technology Industry Trends
  2. 2.2 Multiplex Immunofluorescence (mIF) Technology Industry Drivers
  3. 2.3 Multiplex Immunofluorescence (mIF) Technology Industry Opportunities and Challenges
  4. 2.4 Multiplex Immunofluorescence (mIF) Technology Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Multiplex Immunofluorescence (mIF) Technology Market Perspective (2021-2032)
  2. 3.2 Global Multiplex Immunofluorescence (mIF) Technology Growth Trends by Region
  3. 3.2.1 Global Multiplex Immunofluorescence (mIF) Technology Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Multiplex Immunofluorescence (mIF) Technology Market Size by Region (2021-2026)
  5. 3.2.3 Global Multiplex Immunofluorescence (mIF) Technology Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Multiplex Immunofluorescence (mIF) Technology Revenue by Players
  2. 4.1.1 Global Multiplex Immunofluorescence (mIF) Technology Revenue by Players (2021-2026)
  3. 4.1.2 Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Multiplex Immunofluorescence (mIF) Technology Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Multiplex Immunofluorescence (mIF) Technology Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Multiplex Immunofluorescence (mIF) Technology Key Players Headquarters & Area Served
  7. 4.4 Global Multiplex Immunofluorescence (mIF) Technology Players, Product Type & Application
  8. 4.5 Global Multiplex Immunofluorescence (mIF) Technology Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Multiplex Immunofluorescence (mIF) Technology Market CR5 and HHI
  11. 4.6.3 2025 Multiplex Immunofluorescence (mIF) Technology Tier 1, Tier 2, and Tier 3
5 Multiplex Immunofluorescence (mIF) Technology Market Size by Type
  1. 5.1 Global Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2032)
  3. 5.3 Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Type (2021-2032)
6 Multiplex Immunofluorescence (mIF) Technology Market Size by Application
  1. 6.1 Global Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2032)
  3. 6.3 Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eureka Biotech
  2. 7.1.1 Eureka Biotech Company Information
  3. 7.1.2 Eureka Biotech Business Overview
  4. 7.1.3 Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  6. 7.1.5 Eureka Biotech Recent Developments
  7. 7.2 ICON plc
  8. 7.2.1 ICON plc Company Information
  9. 7.2.2 ICON plc Business Overview
  10. 7.2.3 ICON plc Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  11. 7.2.4 ICON plc Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  12. 7.2.5 ICON plc Recent Developments
  13. 7.3 Discovery Life Sciences
  14. 7.3.1 Discovery Life Sciences Company Information
  15. 7.3.2 Discovery Life Sciences Business Overview
  16. 7.3.3 Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  18. 7.3.5 Discovery Life Sciences Recent Developments
  19. 7.4 Precision Medicine Group
  20. 7.4.1 Precision Medicine Group Company Information
  21. 7.4.2 Precision Medicine Group Business Overview
  22. 7.4.3 Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  24. 7.4.5 Precision Medicine Group Recent Developments
  25. 7.5 Terry Technologies
  26. 7.5.1 Terry Technologies Company Information
  27. 7.5.2 Terry Technologies Business Overview
  28. 7.5.3 Terry Technologies Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Terry Technologies Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  30. 7.5.5 Terry Technologies Recent Developments
  31. 7.6 MGI Tech
  32. 7.6.1 MGI Tech Company Information
  33. 7.6.2 MGI Tech Business Overview
  34. 7.6.3 MGI Tech Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  35. 7.6.4 MGI Tech Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  36. 7.6.5 MGI Tech Recent Developments
  37. 7.7 panovue
  38. 7.7.1 panovue Company Information
  39. 7.7.2 panovue Business Overview
  40. 7.7.3 panovue Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  41. 7.7.4 panovue Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  42. 7.7.5 panovue Recent Developments
  43. 7.8 Biospective
  44. 7.8.1 Biospective Company Information
  45. 7.8.2 Biospective Business Overview
  46. 7.8.3 Biospective Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biospective Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  48. 7.8.5 Biospective Recent Developments
  49. 7.9 iCuraDx
  50. 7.9.1 iCuraDx Company Information
  51. 7.9.2 iCuraDx Business Overview
  52. 7.9.3 iCuraDx Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  53. 7.9.4 iCuraDx Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  54. 7.9.5 iCuraDx Recent Developments
  55. 7.10 Yucebio
  56. 7.10.1 Yucebio Company Information
  57. 7.10.2 Yucebio Business Overview
  58. 7.10.3 Yucebio Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Yucebio Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  60. 7.10.5 Yucebio Recent Developments
  61. 7.11 Flagship Biosciences
  62. 7.11.1 Flagship Biosciences Company Information
  63. 7.11.2 Flagship Biosciences Business Overview
  64. 7.11.3 Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  66. 7.11.5 Flagship Biosciences Recent Developments
  67. 7.12 Lanterne Dx (LDX)
  68. 7.12.1 Lanterne Dx (LDX) Company Information
  69. 7.12.2 Lanterne Dx (LDX) Business Overview
  70. 7.12.3 Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  72. 7.12.5 Lanterne Dx (LDX) Recent Developments
  73. 7.13 Crown Bioscience
  74. 7.13.1 Crown Bioscience Company Information
  75. 7.13.2 Crown Bioscience Business Overview
  76. 7.13.3 Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  78. 7.13.5 Crown Bioscience Recent Developments
8 North America
  1. 8.1 North America Multiplex Immunofluorescence (mIF) Technology Revenue (2021-2032)
  2. 8.2 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2032)
  3. 8.2.1 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026)
  4. 8.2.2 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032)
  5. 8.3 North America Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032)
  6. 8.4 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2032)
  7. 8.4.1 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026)
  8. 8.4.2 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032)
  9. 8.5 North America Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032)
  10. 8.6 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Country
  11. 8.6.1 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021-2026)
  13. 8.6.3 North America Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Multiplex Immunofluorescence (mIF) Technology Revenue (2021-2032)
  2. 9.2 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2032)
  3. 9.2.1 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026)
  4. 9.2.2 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032)
  5. 9.3 Europe Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032)
  6. 9.4 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2032)
  7. 9.4.1 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026)
  8. 9.4.2 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032)
  9. 9.5 Europe Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032)
  10. 9.6 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Country
  11. 9.6.1 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021-2026)
  13. 9.6.3 Europe Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Multiplex Immunofluorescence (mIF) Technology Revenue (2021-2032)
  2. 10.2 China Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2032)
  3. 10.2.1 China Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026)
  4. 10.2.2 China Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032)
  5. 10.3 China Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032)
  6. 10.4 China Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2032)
  7. 10.4.1 China Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026)
  8. 10.4.2 China Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032)
  9. 10.5 China Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Multiplex Immunofluorescence (mIF) Technology Revenue (2021-2032)
  2. 11.2 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2032)
  3. 11.2.1 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026)
  4. 11.2.2 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032)
  5. 11.3 Asia Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032)
  6. 11.4 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2032)
  7. 11.4.1 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026)
  8. 11.4.2 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032)
  9. 11.5 Asia Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032)
  10. 11.6 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Country
  11. 11.6.1 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021-2026)
  13. 11.6.3 Asia Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue (2021-2032)
  2. 12.2 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Type (2027-2032)
  5. 12.3 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Application (2027-2032)
  9. 12.5 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Country
  11. 12.6.1 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Multiplex Immunofluorescence (mIF) Technology Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst